35 reports

  • II. BUSINESS ENVIRONMENT
  • Biologics Sales Volumes and Forecasts Summary

In 2008, monoclonal antibody sales were only ##. ## billion Yuan.

  • Diagnostics
  • Interferon
  • Medical Biotechnology
  • China
  • Demand
  • IV. BIOLOGICS SALES VOLUMES AND FORECASTS
  • IV. BIOLOGICS SALES VOLUMES AND FORECASTS

In 2008, monoclonal antibody sales were only ##. ## billion Yuan.

  • Interferon
  • China
  • Demand
  • Market Size
  • Dongguan Winnerway Bio-Tech Co., Ltd.

Until now, the sales volume of monoclonal antibodies is over ## billion Yuan, and increased ##% each year.

  • Interferon
  • China
  • Demand
  • Supply
  • Shenzhen Keing Biotech Co., Ltd
  • NS5B polymerase

CD##+ T cells secrete cytokines that increase antibody production by B cells.

  • Interferon
  • Bristol-Myers Squibb Company
  • Gilead Sciences, Inc.
  • Merck & Co., Inc.
  • Roche Group

UNTIL NOW, THE SALES VOLUME OF MONOCLONAL ANTIBODIES IS OVER ## BILLION YUAN, AND INCREASED ##% EACH YEAR.

  • Interferon
  • China
  • Demand
  • Market Size
  • Supply

Monoclonal antibodies such as mepolizumab and omalizumab are sometimes effective.

  • Cough And Cold
  • China
  • Demand
  • Market Size
  • Trade

Chart ##: Imatinib Mesylate Sales Volume and Market Share (million Yuan) Rituximab Table ##: Imatinib Mesylate Major Producer and Their Market Share (million Yuan) Rituximab is a chimeric monoclonal antibody against the protein CD##.

  • Interferon
  • China
  • Trade
  • Lijun Pharmaceutical Co., Ltd.
  • Shanghai Schering-Plough Pharmaceutical Company, Ltd

Monoclonal antibodies such as mepolizumab and omalizumab are sometimes effective.

  • Cough And Cold
  • Interferon
  • China
  • Demand
  • Market Size

Pasteur Institute NA NA MONOCLONAL ANTIBODY TO ANTAGONIZE FCGRIIA FOR AUTOIMMUNE ARTHRITIS, PULMONARY INFLAMMATION, SYSTEMIC ANAPHYLAXIS AND THROMBOCYTOPENIA - DRUG PROFILE Drug Name Company/ Institute Name Licensed From Company Development Partner Product Description

  • Cough And Cold
  • Therapy
  • United States
  • World
  • Product Initiative

MONOCLONAL ANTIBODIES ACTS AGAINST CELLS EXPRESSING CLAUDIN ##.

  • Antiviral
  • Hepatitis
  • Interferon
  • Therapy
  • Bristol-Myers Squibb Company
  • HEPATITIS C - PIPELINE BY AMARILLO BIOSCIENCES INC, H1 2018

MONOCLONAL ANTIBODIES ACTS AGAINST CELLS EXPRESSING CLAUDIN ##.

  • Hepatitis
  • Interferon
  • Research And Development
  • Therapy
  • Bristol-Myers Squibb Company

Most recently she served as the Worldwide Brand Director at Novartis Pharmaceuticals Corporation, where she was the global launch lead for Aimovig®, the first monoclonal antibody approved by the U. S.

  • Clinical Trial
  • Cough And Cold
  • HIV AIDS
  • United States
  • AcelRx Pharmaceuticals, Inc.

The drug candidate is a monoclonal antibody that inhibits binding of IL-## to the ST## receptor.

  • Cough And Cold
  • Pharmaceutical
  • Therapy
  • United States
  • Product Initiative

Our VB-## platform comprises classical anti-MOSPD## monoclonal antibodies for inflammatory indications, as well as bi-specific antibody candidates for oncology.

  • Cough And Cold
  • Drug Development
  • Interferon
  • World
  • Product Initiative
  • INTERFERON ALFA - DRUG PROFILE

Veltuzumab is an anti-CD## monoclonal antibody.

  • Cough And Cold
  • Interferon
  • Monoclonal Antibody
  • United States
  • BioLineRx Ltd.
  • 5. ALL THE TRIALS INCLUDED ARE UNIQUE TRIALS.

Trials conducted by companies in Phase II and Phase ## stand at ## and ## respectively.

  • Interferon
  • Neurological Disorder
  • Neurology
  • World
  • Product Initiative

It also develops a product candidate, an anti-CD## monoclonal antibody that inhibits the production of adenosine produced by the tumor cells.

  • Cough And Cold
  • Pharmaceutical
  • Therapy
  • United States
  • Vernalis plc
  • ZIOPHARM ONCOLOGY INC
  • Interferon Alpha (IFNA) - Dormant Projects

These results further support the superiority of a polyclonal antibody strategy over monoclonal antibodies in the treatment of SLE.

  • Interferon
  • Musculoskeletal Disorder
  • Therapy
  • United States
  • Neovacs SA
  • 5. All the trials included are unique trials.

While only an early look at the Week ## timepoint, the data continue to be impressive and suggestive of a highly efficacious anti-CD## monoclonal antibody with a manageable safety profile that can be administered in a convenient one-hour infusion.

  • Clinical Trial
  • Cough And Cold
  • Interferon
  • Neurological Disorder
  • Biogen Idec Inc.

## ## ## ## United States ## ## ## ## ## ## ## ## Germany ## ## ## ## ## ## ## ## United Kingdom ## ## ## ## ## ## ## ## Italy ## ## ## ## ## ## ## ## Canada ## ## ## ## ## ## ## ## France ## ## ## ## ## ## ## ## CLINICA

  • Drug Development
  • Interferon
  • World
  • Product Initiative
  • Shionogi & Co., Ltd.
  • 5. All the trials included are unique trials.

The prominent features of this report are - ##.

  • Clinical Trial
  • Cough And Cold
  • Interferon
  • Neurological Disorder
  • Biogen Idec Inc.

The prominent features of this report are - ##.

  • Cough And Cold
  • Interferon
  • Neurological Disorder
  • Pharmaceutical
  • Biogen Idec Inc.
  • BIOLINGUS AG - PIPELINE BY INDICATION, 2016
  • BIOLINGUS AG - UNKNOWN STAGE PIPELINE PRODUCTS

Monoclonal antibody acts by inhibiting IL-## subunit beta.

  • Interferon
  • Medical Biotechnology
  • Pharmaceutical
  • Therapy
  • BioLingus
  • 5. All the trials included are unique trials.

Slawomir Jaros, PhD - Head of Operations and Science at Mabion S. A. : Published reports confirm the efficacy of the treatment of patients with multiple sclerosis with the use of antibodies reacting with B-lymphocytes.

  • Clinical Trial
  • Cough And Cold
  • Interferon
  • Neurological Disorder
  • Biogen Idec Inc.

Humabs BioMed' s proprietary platform, cellclone, delivers a pipeline of human monoclonal antibodies, and demonstrates the antibodies effectiveness in both in-vivo and in-vitro.

  • Cough And Cold
  • Interferon
  • Medical Biotechnology
  • United States
  • Hemispherx Biopharma, Inc.

Hoffmann-La Roche Ltd ## ## ## ## ## ## ## Sanofi ## ## ## ## ## ## ## Novartis AG ## ## ## ## ## ## ## Conatus Pharmaceuticals Inc ## ## ## ## ## ## ## GlaxoSmithKline Plc ## ## ## ## ## ## ## Norgine BV ## ## ## ## ## ## ## Otsuka Holdings Co Ltd ## ## ## ## ## ## ## Ocera Therapeutics Inc ##

  • Clinical Trial
  • Digestive System Disorder
  • Interferon
  • Therapy
  • World

Monoclonal antibody elicits antiviral activity.

  • Cough And Cold
  • Interferon
  • Therapy
  • Vaccine
  • Hemispherx Biopharma, Inc.

Patients were randomized ##:##:## to receive ## mg of emricasan, ## mg of emricasan, or placebo twice daily for ## weeks.

  • Interferon
  • Monoclonal Antibody
  • Pharmaceutical
  • World
  • Product Initiative

Assessment of Clinical Usefulness in Preventing Reactivation of HBV Infection Efficacy of the Vaccine Against Hepatitis B in Patients under Immunosuppressive Treatment with past Hepatitis B but Low Antibody Titers.

  • Hepatitis
  • Infectious Disease
  • Interferon
  • World
  • GlaxoSmithKline plc
  • Clinical Trial profile. 647 Trial Title

THE PROMINENT FEATURES OF THIS REPORT ARE - ##.

  • Clinical Trial
  • Digestive System Disorder
  • Interferon
  • Pharmaceutical
  • World